Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Nutex Health (NUTX) EBITDA Margin (2017 - 2025)

Nutex Health's EBITDA Margin history spans 16 years, with the latest figure at 25.96% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1841.0% year-over-year to 25.96%; the TTM value through Dec 2025 reached 31.49%, up 426.0%, while the annual FY2025 figure was 31.49%, 426.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 25.96% at Nutex Health, down from 48.68% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1940.66% in Q1 2022 and bottomed at 1509.7% in Q3 2022.
  • The 5-year median for EBITDA Margin is 7.72% (2022), against an average of 24.25%.
  • The largest annual shift saw EBITDA Margin soared 214668bps in 2022 before it plummeted -194855bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 37.39% in 2021, then skyrocketed by 123bps to 8.47% in 2022, then tumbled by -543bps to 37.53% in 2023, then skyrocketed by 218bps to 44.36% in 2024, then plummeted by -41bps to 25.96% in 2025.
  • Per Business Quant, the three most recent readings for NUTX's EBITDA Margin are 25.96% (Q4 2025), 48.68% (Q3 2025), and 13.8% (Q2 2025).